Related Experiment Video
Updated: Aug 8, 2025
An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects
Published on: January 9, 2020
Single-Cell Metabolomics-Based Strategy for Studying the Mechanisms of Drug Action
Guizhen Zhu1, Wenmei Zhang1, Yaoyao Zhao1
1Center of Excellence for Environmental Safety and Biological Effects, Beijing Key Laboratory for Green Catalysis and Separation, Department of Chemistry, Beijing University of Technology, Beijing 100124, China.
Abstract:
Studying the mechanisms of drug antitumor activity at the single-cell level can provide information about the responses of cell subpopulations to drug therapy, which is essential for the accurate treatment of cancer. Due to the small size of single cells and the low contents of metabolites, metabolomics-based approaches to studying the mechanisms of drug action at the single-cell level are lacking. Herein, we develop a label-free platform for studying the mechanisms of drug action based on single-cell metabolomics (sMDA-scM) by integrating intact living-cell electro-launching ionization mass spectrometry (ILCEI-MS) with metabolomics analysis. Using this platform, we reveal that non-small-cell lung cancer (NSCLC) cells treated by gefitinib can be clustered into two cell subpopulations with different metabolic responses. The glutathione metabolic pathway of the subpopulation containing 14.4% of the cells is not significantly affected by gefitinib, exhibiting certain resistance characteristics. The presence of these cells masked the judgment of whether cysteine and methionine metabolic pathway was remarkably influenced in the analysis of overall average results, revealing the heterogeneity of the response of single NSCLC cells to gefitinib treatment. The findings provide a basis for evaluating the early therapeutic effects of clinical medicines and insights for overcoming drug resistance in NSCLC subpopulations.
Insights
A new platform reveals cancer cell heterogeneity in drug response. Some non-small cell lung cancer cells show resistance to gefitinib by maintaining glutathione metabolism, masking overall treatment effects.
Area of Science:
- Oncology
- Metabolomics
- Mass Spectrometry
Background:
- Understanding single-cell drug responses is crucial for effective cancer therapy.
- Current metabolomics methods struggle with the low metabolite levels in single cells.
- Identifying drug-resistant subpopulations is key to improving cancer treatment.
Purpose of the Study:
- To develop a label-free platform for single-cell metabolomics analysis of drug action mechanisms.
- To investigate the metabolic heterogeneity of non-small cell lung cancer (NSCLC) cells responding to gefitinib.
- To uncover insights into drug resistance at the single-cell level.
Main Methods:
- Development of a novel platform integrating intact living-cell electro-launching ionization mass spectrometry (ILCEI-MS) with metabolomics.
- Application of the platform to analyze gefitinib-treated NSCLC cells.
- Clustering of cells based on distinct metabolic profiles.
Main Results:
- Identified two distinct NSCLC cell subpopulations with differing metabolic responses to gefitinib.
- One subpopulation (14.4% of cells) showed unaffected glutathione metabolism, indicating resistance.
- Observed that resistant cells masked the impact on cysteine and methionine metabolism in bulk analysis, highlighting heterogeneity.
Conclusions:
- The developed single-cell metabolomics platform (sMDA-scM) effectively reveals drug action mechanisms and cellular heterogeneity.
- Drug resistance in NSCLC can be attributed to specific subpopulations with distinct metabolic pathways.
- Findings offer a basis for evaluating drug efficacy and overcoming resistance in cancer therapy.
More Related Videos
08:28Author Spotlight: Advancing Metabolomics Analysis of Rare Hematopoietic Stem Cells
Published on: February 23, 2024
07:55Integrated Cell Manipulation Platform Coupled with the Single-probe for Mass Spectrometry Analysis of Drugs and Metabolites in Single Suspension Cells
Published on: June 21, 2019